Epigenetics of colorectal cancer: biomarker and therapeutic potential

Gerhard Jung, Eva Hernández-Illán, Leticia Moreira, Francesc Balaguer, Ajay Goel, Gerhard Jung, Eva Hernández-Illán, Leticia Moreira, Francesc Balaguer, Ajay Goel

Abstract

Colorectal cancer (CRC), a leading cause of cancer-related death worldwide, evolves as a result of the stepwise accumulation of a series of genetic and epigenetic alterations in the normal colonic epithelium, leading to the development of colorectal adenomas and invasive adenocarcinomas. Although genetic alterations have a major role in a subset of CRCs, the pathophysiological contribution of epigenetic aberrations in this malignancy has attracted considerable attention. Data from the past couple of decades has unequivocally illustrated that epigenetic marks are important molecular hallmarks of cancer, as they occur very early in disease pathogenesis, involve virtually all key cancer-associated pathways and, most importantly, can be exploited as clinically relevant disease biomarkers for diagnosis, prognostication and prediction of treatment response. In this Review, we summarize the current knowledge on the best-studied epigenetic modifications in CRC, including DNA methylation and histone modifications, as well as the role of non-coding RNAs as epigenetic regulators. We focus on the emerging potential for the bench-to-bedside translation of some of these epigenetic alterations into clinical practice and discuss the burgeoning evidence supporting the potential of emerging epigenetic therapies in CRC as we usher in the era of precision medicine.

Conflict of interest statement

Competing interests

F.B. declares that he has endoscopic equipment on loan from Fujifilm, and has received an honorarium for consultancy from Sysmex and speaker’s fees from Norgine. The other authors declare no competing interests.

Figures

Figure 1 |. Principles of epigenetics.
Figure 1 |. Principles of epigenetics.
The main epigenetic modifications implicated in colorectal cancer (CRC) — including DNA methylation (1), histone modifications (2), long noncoding RNAs (lncRNAs) (3) and microRNAs (miRNAs; also known as miRs) (4) — are shown. Hypermethylation of CpG islands in promoter regions of tumour-suppressor genes placed by DNA-methyl transferases (DNMTs) inhibits gene expression and can favor tumorigenesis, (1). If hypomethylation occurs in retrotransposable elements (such as LINE-1 elements), these are activated and insert themselves in distant fragile sites, leading to genomic instability. Hypomethylation of promoters or distant super-enhancers can enhance expression of proto-oncogenes. Acetyl-groups are placed by histone acetyl-transferases (HATs) and removed by histone deacetylases (HDACs); acetylation generally weakens the compaction status of the chromatin and makes the DNA accessible to transcription factors (2). Histone methylation is regulated by histone methyltransferases (HMTs) and histone demethylases (HDMs); methyl groups on histone tails create docking sites for proteins that can repress or increase gene expression (2). lncRNAs influence gene and protein expression through different molecular mechanisms (3). They can enhance transcription by recruiting transcription factors or repress transcription by decoying transcription factors and preventing their recruitment to transcriptional start sites. LncRNAs can also restore translation by ‘sponging’ miRNAs that would otherwise prevent translation of their corresponding mRNA. LncRNAs can also directly inhibit translation. The biogenesis of miRNAs starts with the transcription of the miRNA gene by RNA polymerase II (RNA Pol II) (4). The double-stranded, hairpin-formed pri-miRNA is processed to the pre-miRNA by Drosha/DGCR8 and then translocated to the cytoplasm by exportin-5. The RNAse III enzyme DICER cuts the hairpin loop, resulting in a double-stranded miRNA-miRNA molecule. The RNA-induced silencing complex (RISC) incorporates one of the strands and mediates its interaction with the target mRNA, leading either to translational inhibition or mRNA degradation.
Figure 2 |. Role of miRNAs and…
Figure 2 |. Role of miRNAs and lncRNAs in CRC.
The roles of selected long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) in regulating virtually all important signalling pathways relevant to colorectal cancer (CRC) are shown. Activation of the RAS-RAF-MEK pathway, which leads to enhanced proliferation and can modulate treatment responses, can occur via downregulation of miR-143 and/or upregulation of miR-31 (1). miR-21, the most frequently overexpressed miRNA in CRC, can favour cancer progression by targeting PTEN, preventing PIP3 dephosphorylation and resulting in hyperactivation of the PI3K-AKT pathway (2). In addition, miR-21 can target PDCD4, which is thought to be an important mediator in apoptosis effector pathways. (3) In the presence of DNA damage, p53 holds the cell cycle at the G1-S checkpoint to allow DNA repair or to induce apoptosis if repair is not possible. In a positive feedback loop, p53 increases the expression of miR-34a (which is frequently downregulated in CRC), resulting in enhanced p53 activity (4). Moreover, miR-34a directly targets SMAD4, a key effector in TGFβ signalling. Thus, downregulation of miR-34a enhances TGFβ signalling and results in enhanced epithelial-mesenchymal transition (EMT) and tumour cell invasion, (5). Loss of E-cadherin in epithelial cells leads to a loss of contact inhibition, which favours cell growth, migration and invasion via β-catenin-TCF signalling (6). In CRC cells, miR-29a and the lncRNA HOTAIR have been described to decrease the expression of E-cadherin. miR-135 directly targets and downregulates APC, which, under normal conditions, degrades β-catenin, resulting in downstream activation of the WNT-β-catenin pathway (7). When tumours grow rapidly, hypoxia stimulates the formation of new blood vessels through angiogenesis, which is crucial for tumour survival and is regulated by the VEGF pathway. VEGF is a direct target of miR-126 and is also repressed by the lncRNA GAS5, and both are frequently downregulated in CRC, (8).
Figure 3 |. Epigenetic biomarkers in CRC.
Figure 3 |. Epigenetic biomarkers in CRC.
Given their emerging roles in colorectal cancer (CRC), epigenetic marks or regulators can be exploited as clinically relevant disease biomarkers for diagnosis, prognostication and prediction of treatment response. Blood-based biomarkers (serum or plasma) might have diagnostic, prognostic or predictive value in CRC. Tissue-based biomarkers in endoscopically resected lesions might also be used clinically to improve prediction of the risk of invasion of early lesions (carcinoma in situ or pT1) and guide treatment options and surveillance strategies. Stool-based biomarkers (from abraded carcinoma cells) have a number of potential diagnostic applications; for example, Cologuard (NDRG4 methylation, BMP3 methylation and KRAS mutation) for screening of adenomas and early-stage CRC. Endoscopic biopsies of normal rectal mucosa (which is less invasive than endoscopic resection) could be used to identify patients at a high risk of metachronous or synchronous lesions owing to ‘field defect’ in normal rectal mucosa; for example, methylation of miR-137 in endoscopic biopsy tissue is an independent risk factor for ulcerative colitis-associated CRC. Finally, tissue-based biomarkers in surgical specimens (primary metastatic or tumours) might also have prognostic or predictive roles.

References

    1. Bray F et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin 68, 394–424 (2018).
    1. ECIS - European Cancer Information System From , accessed on 13/08/2019.
    1. Siegel RL, Miller KD & Jemal A Cancer statistics of American 2019. CA. Cancer J. Clin 69, 7–34 (2019).
    1. Goel A & Boland CR Epigenetics of colorectal cancer. Gastroenterology 143, 1442–1460.e1 (2012).
    1. Dienstmann R et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer 17, 79–92 (2017).
    1. Herman JG et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. U. S. A 95, 6870–5 (1998).
    1. Suter CM, Martin DI & Ward RL Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. Int. J. Colorectal Dis 19, 95–101 (2004).
    1. Strubberg AM & Madison BB MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications. Dis Model Mech 10, 197–214 (2017).
    1. Chen X et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28, 1385–92 (2009).
    1. Kanai Y & Hirohashi S Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 28, 2434–42 (2007).
    1. Gardiner-Garden M & Frommer M CpG islands in vertebrate genomes. J. Mol. Biol 196, 261–282 (1987).
    1. Ng J & Yu J Promoter Hypermethylation of Tumour Suppressor Genes as Potential Biomarkers in Colorectal Cancer. Int. J. Mol. Sci 16, 2472–2496 (2015).
    1. Lao VV & Grady WM Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol 8, 686–700 (2011).
    1. Okugawa Y, Grady WM & Goel A Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology 149, 1204–1225e12 (2015).
    1. Bihl MP, Foerster A, Lugli A & Zlobec I Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing. J. Transl. Med 10, 173 (2012).
    1. Esteller M et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J. Clin. Oncol 19, 299–304 (2001).
    1. Esteller M et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res. 60, 129–33 (2000).
    1. JM C et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 58, 3455–3460 (1998).
    1. Liang T-J et al. APC hypermethylation for early diagnosis of colorectal cancer: a meta-analysis and literature review. Oncotarget 8, 46468–46479 (2017).
    1. Yang X et al. Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer. Cancer Cell 26, 577–590 (2014).
    1. Sunami E, de Maat M, Vu A, Turner RR & Hoon DSB LINE-1 hypomethylation during primary colon cancer progression. PLoS One 6, e18884 (2011).
    1. Nagai Y et al. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer. Oncotarget 8, 11906–11916 (2017).
    1. Hur K et al. Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut 63, 635–646 (2014).
    1. Milicic A et al. Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. Cancer Res. 68, 7760–7768 (2008).
    1. Pérez RF, Tejedor JR, Bayón GF, Fernández AF & Fraga MF Distinct chromatin signatures of DNA hypomethylation in aging and cancer. Aging Cell 17, e12744 (2018).
    1. Baba Y et al. Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology 139, 1855–64 (2010).
    1. Luo J, Li Y-N, Wang F, Zhang W-M & Geng X S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer. Int. J. Biol. Sci 6, 784–95 (2010).
    1. Antelo M et al. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS One 7, e45357 (2012).
    1. Baba Y et al. Long Interspersed Element-1 Methylation Level as a Prognostic Biomarker in Gastrointestinal Cancers. in Digestion 97, 26–30 (2018).
    1. Ogino S et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int. J. Cancer 122, 2767–2773 (2008).
    1. Chi P, Allis CD & Wang GG Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nature Reviews Cancer 10, 457–469 (2010).
    1. Hanigan CL et al. An Inactivating Mutation in HDAC2 Leads to Dysregulation of Apoptosis Mediated by APAF1. Gastroenterology 135, 1654–1664.e2 (2008).
    1. Gargalionis AN, Piperi C, Adamopoulos C & Papavassiliou AG Histone modifications as a pathogenic mechanism of colorectal tumorigenesis. Int. J. Biochem. Cell Biol 44, 1276–1289 (2012).
    1. Struhl K Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12, 599–606 (1998).
    1. Audia JE & Campbell RM Histone Modifications and Cancer. Cold Spring Harb. Perspect. Biol 8, a019521 (2016).
    1. Vaish V, Khare T, Verma M & Khare S Epigenetic Therapy for Colorectal Cancer. in Methods in molecular biology (Clifton, N.J.) 1238, 771–78210.1002/ijc.26484 2. Oh T, Kim N, Moon Y, et al. Genome-wide iden, 2015).
    1. Huang T et al. Targeting histone methylation for colorectal cancer. Therap. Adv. Gastroenterol 10, 114–131 (2017).
    1. Salz T et al. hSETD1A regulates Wnt target genes and controls tumor growth of colorectal cancer cells. Cancer Res. 74, 775–86 (2014).
    1. Greer EL & Shi Y Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet 13, 343–57 (2012).
    1. Esteller M Non-coding RNAs in human disease. Nat. Rev. Genet 12, 861–874 (2011).
    1. Kita Y et al. Noncoding RNA and colorectal cancer: Its epigenetic role. J. Hum. Genet 62, 41–47 (2017).
    1. Hombach S & Kretz M Non-coding RNAs: Classification, Biology and Functioning. Adv. Exp. Med. Biol 937, 3–17 (2016).
    1. Croce CM Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet 10, 704–714 (2009).
    1. Lujambio A et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. U. S. A 105, 13556–61 (2008).
    1. Ma Y et al. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int. J. cancer 130, 2077–87 (2012).
    1. A.A. S, D.M. E & F.J. S OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer. Cancer Res. 76, 3666–3670 (2016).
    1. Guttman M & Rinn JL Modular regulatory principles of large non-coding RNAs. Nature 482, 339–346 (2012).
    1. Yang Y, Du Y, Liu X & Cho WC Involvement of Non-coding RNAs in the Signaling Pathways of Colorectal Cancer. Adv. Exp. Med. Biol 937, 19–51 (2016).
    1. Luo J et al. Long non-coding RNAs: a rising biotarget in colorectal cancer. Oncotarget 8, 22187–22202 (2017).
    1. Kogo R et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 71, 6320–6 (2011).
    1. Luo Z-F et al. Clinical significance of HOTAIR expression in colon cancer. World J. Gastroenterol 22, 5254–9 (2016).
    1. WU Z-H et al. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol. Rep 32, 395–402 (2014).
    1. Schwarzenbach H Biological and Clinical Relevance of H19 in Colorectal Cancer Patients. EBioMedicine 13, 9–10 (2016).
    1. Bai J et al. Integrating analysis reveals microRNA-mediated pathway crosstalk among Crohn’s disease, ulcerative colitis and colorectal cancer. Mol Biosyst 10, 2317–2328 (2014).
    1. Goel A et al. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res. 63, 1608–14 (2003).
    1. Geigl JB, Obenauf AC, Schwarzbraun T & Speicher MR Defining ‘chromosomal instability’. Trends Genet. 24, 64–9 (2008).
    1. Fearon ER & Vogelstein B A genetic model for colorectal tumorigenesis. Cell 61, 759–67 (1990).
    1. Lynch HT, Lynch JF, Lynch PM & Attard T Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. Fam. Cancer 7, 27–39 (2008).
    1. Boland CR & Goel A Microsatellite Instability in Colorectal Cancer. Gastroenterology 138, 2073–2087.e3 (2010).
    1. Pussila M et al. Mlh1 deficiency in normal mouse colon mucosa associates with chromosomally unstable colon cancer. Carcinogenesis 39, 788–797 (2018).
    1. Haraldsdottir S et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 147, 1308–1316.e1 (2014).
    1. Popat S, Hubner R & Houlston RS Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis. J. Clin. Oncol 23, 609–618 (2005).
    1. Des Guetz G et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur. J. Cancer 45, 1890–1896 (2009).
    1. Weisenberger DJ et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet 38, 787–93 (2006).
    1. Toyota M et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U. S. A 96, 8681–8686 (1999).
    1. Weisenberger DJ et al. Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history. Cancer Epidemiol. Biomarkers Prev 24, 512–519 (2015).
    1. Jia M, Gao X, Zhang Y, Hoffmeister M & Brenner H Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clin. Epigenetics 8, 1–14 (2016).
    1. Guinney J et al. The consensus molecular subtypes of colorectal cancer. Nat. Med 21, 1350–1356 (2015).
    1. Bilgin B, Sendur MAN, Bülent Akıncı M, Şener Dede D & Yalçın B Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. Curr. Med. Res. Opin 33, 749–759 (2017).
    1. Le DT et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med 372, 2509–2520 (2015).
    1. Le DT et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (80-.) 357, 409–413 (2017).
    1. Fessler E et al. TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Mol. Med 8, 745–760 (2016).
    1. Akao Y et al. Role of anti-oncomirs miR-143 and −145 in human colorectal tumors. Cancer Gene Ther 17, 398–408 (2010).
    1. Akao Y et al. Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143. Cancer Sci. 109, 1455–1467 (2018).
    1. Fei B, Wang X & Fang X MicroRNA-143 replenishment re-sensitizes colorectal cancer cells harboring mutant, but not wild-type, KRAS to paclitaxel treatment. Tumor Biol. 37, 5829–5835 (2016).
    1. Gao J et al. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer. Oncogene 34, 4142–52 (2015).
    1. Sun C et al. miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-β/Smad4 pathway. World J. Gastroenterol 23, 1816–1827 (2017).
    1. Rokavec M et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Invest 124, 1853–67 (2014).
    1. Aherne ST et al. Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression. BMC Cancer 15, 329 (2015).
    1. Hiyoshi Y et al. Increased microRNA-34b and −34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer. PLoS One 10, e0124899 (2015).
    1. Wang M et al. The quantitative analysis by stem-loop real-time PCR revealed the microRNA-34a, microRNA-155 and microRNA-200c overexpression in human colorectal cancer. Med. Oncol 29, 3113–8 (2012).
    1. Wu Y et al. MicroRNA-21 (Mir-21) Promotes Cell Growth and Invasion by Repressing Tumor Suppressor PTEN in Colorectal Cancer. Cell. Physiol. Biochem 43, 945–958 (2017).
    1. Peacock O et al. Inflammation and MiR-21 Pathways Functionally Interact to Downregulate PDCD4 in Colorectal Cancer. PLoS One 9, e110267 (2014).
    1. Horiuchi A, Iinuma H, Akahane T, Shimada R & Watanabe T Prognostic significance of PDCD4 expression and association with microRNA-21 in each Dukes’ stage of colorectal cancer patients. Oncol. Rep 27, 1384–92 (2012).
    1. Sun D et al. MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol Chem 288, 9508–9518 (2013).
    1. Manceau G et al. Hsa-miR-31–3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res 20, 3338–3347 (2014).
    1. Igarashi H et al. Association of MicroRNA-31–5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. Ann Surg Oncol 22, 2640–2648 (2015).
    1. Rmali KA, Puntis MCA & Jiang WG Tumour-associated angiogenesis in human colorectal cancer. Color. Dis 9, 3–14 (2007).
    1. Zhang Y et al. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep 30, 1976–1984 (2013).
    1. Yin J et al. Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer. Chin J Cancer Res 26, 95–103 (2014).
    1. Liu Y et al. Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer. Genes Chromosom. Cancer 53, 358–365 (2014).
    1. Fiala O et al. The association of miR-126–3p, miR-126–5p and miR-664–3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol 39, 1010428317709283 (2017).
    1. Quintero E et al. Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. N. Engl. J. Med 366, 697–706 (2012).
    1. Compton CC Optimal Pathologic Staging: Defining Stage II Disease. Clin. Cancer Res 13, 6862s–6870s (2007).
    1. Tänzer M et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One 5, e9061 (2010).
    1. He Q et al. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. Cancer Genet. Cytogenet 202, 1–10 (2010).
    1. Wu D et al. Detection of Colorectal Cancer Using a Simplified SEPT9 Gene Methylation Assay Is a Reliable Method for Opportunistic Screening. J. Mol. Diagn 18, 535–45 (2016).
    1. Fu B et al. Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer. Dis. Markers 2018, 6437104 (2018).
    1. Lofton-Day C et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem 54, 414–23 (2008).
    1. Grützmann R et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 3, e3759 (2008).
    1. deVos T et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem 55, 1337–46 (2009).
    1. Warren JD et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 9, 133 (2011).
    1. Ahlquist DA et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin. Gastroenterol. Hepatol 10, 272–7.e1 (2012).
    1. Xue M, Lai SC, Xu ZP & Wang LJ Noninvasive DNA methylation biomarkers in colorectal cancer: A systematic review. J. Dig. Dis 16, 699–712 (2015).
    1. He N et al. The Pathological Features of Colorectal Cancer Determine the Detection Performance on Blood ctDNA. Technol. Cancer Res. Treat 17, 1533033818791794 (2018).
    1. Song L et al. The SEPT9 gene methylation assay is capable of detecting colorectal adenoma in opportunistic screening. Epigenomics 9, 599–610 (2017).
    1. Song L, Jia J, Peng X, Xiao W & Li Y The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis. Sci. Rep 7, 1–12 (2017).
    1. Bergheim J et al. Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: A prospective observational cohort study. Br. J. Cancer 118, 1217–1228 (2018).
    1. Church TR et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63, 317–25 (2014).
    1. Li M et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol 27, 858–63 (2009).
    1. Itzkowitz SH et al. Improved fecal DNA test for colorectal cancer screening. Clin. Gastroenterol. Hepatol 5, 111–117 (2007).
    1. Baek YH et al. Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients. Dis. Colon Rectum 52, 1452–9; discussion 1459–63 (2009).
    1. Kisiel JB et al. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther 37, 546–554 (2013).
    1. Lu H et al. DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA. Oncol. Lett 8, 1751–1756 (2014).
    1. Chen WD et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl. Cancer Inst 97, 1124–1132 (2005).
    1. Carmona FJ et al. DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer. Cancer Prev. Res. (Phila) 6, 656–65 (2013).
    1. Ned RM, Melillo S & Marrone M Fecal DNA testing for Colorectal Cancer Screening: the ColoSure™ test. PLoS Curr. 3, RRN1220 (2011).
    1. Tang D et al. Diagnostic and prognostic value of the methylation status of secreted frizzledrelated protein 2 in colorectal cancer. Clin. Investig. Med 34, 88–95 (2011).
    1. Barták BK et al. Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. Epigenetics 12, 751–763 (2017).
    1. Park S-K et al. Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population? Intest. Res 15, 495–501 (2017).
    1. Glöckner SC et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 69, 4691–9 (2009).
    1. Zhang H, Zhu Y-QQ, Wu Y-QQ, Zhang P & Qi J Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer. World J Gastroenterol. 20, 6329–35 (2014).
    1. Imperiale TF et al. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med 370, 1287–97 (2014).
    1. US Preventive Services Task Force, K. et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 315, 2564–2575 (2016).
    1. van Lanschot MCJ et al. Molecular stool testing as an alternative for surveillance colonoscopy: A cross-sectional cohort study. BMC Cancer 17, 1–8 (2017).
    1. Vasen HFA et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62, 812–823 (2013).
    1. Giardiello FM et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 147, 502–26 (2014).
    1. Anderson JC Pathogenesis and management of serrated polyps: current status and future directions. Gut Liver 8, 582–589 (2014).
    1. Ogino S et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J. Natl. Cancer Inst 100, 1734–1738 (2008).
    1. Ahn JB et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 117, 1847–54 (2011).
    1. Rhee Y-Y et al. Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level. Ann. Surg. Oncol 19, 3441–8 (2012).
    1. Nakayama H et al. Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett. 188, 115–119 (2002).
    1. Nakayama H et al. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int. J. cancer 105, 491–493 (2003).
    1. Zou H-Z et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res 8, 188–91 (2002).
    1. Lecomte T et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int. J. Cancer 100, 542–548 (2002).
    1. Xing X-B et al. The Prognostic Value of p16 Hypermethylation in Cancer: A Meta-Analysis. PLoS One 8, e66587 (2013).
    1. Mitomi H et al. Aberrant p16((INK4a)) methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity. J. Cancer Res. Clin. Oncol 136, 323–331 (2010).
    1. Shen L et al. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin. Cancer Res 13, 6093–6098 (2007).
    1. Kim JC et al. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann. Surg. Oncol 17, 1767–76 (2010).
    1. Liang JT et al. Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival. Oncology 57, 149–56 (1999).
    1. Sun W et al. The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients. Oncol. Rep 31, 1466–1472 (2014).
    1. Hochhauser D et al. A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O-6-Methylguanine-DNA Methyltransferase Promoter. Mol. Cancer Ther 12, 809 LP–818 (2013).
    1. Nagasaka T et al. Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. Clin. Cancer Res 9, 5306–12 (2003).
    1. Amatu A et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin. Cancer Res 19, 2265–72 (2013).
    1. Park SJ et al. TFAP2E methylation status and prognosis of patients with radically resected colorectal cancer. Oncol. 88, 122–132 (2015).
    1. Ebert MPA et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N. Engl. J. Med 366, 44–53 (2012).
    1. Murcia O et al. TFAP2E methylation and expression status does not predict response to 5-FU-based chemotherapy in colorectal cancer. Clin. Cancer Res 24, 2820–2827 (2018).
    1. Herbst A et al. Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer. Int. J. cancer 140, 2134–2144 (2017).
    1. Philipp AB et al. Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer. BMC Cancer 14, 245 (2014).
    1. Herbst A et al. Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am. J. Gastroenterol 106, 1110–8 (2011).
    1. Wallner M et al. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin. Cancer Res 12, 7347–52 (2006).
    1. Herbst A et al. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. Eur. J. Gastroenterol. Hepatol 21, 565–569 (2009).
    1. Huang Z-H, Li L-H, Yang F & Wang J-F Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J. Gastroenterol 13, 950–4 (2007).
    1. Ashktorab H et al. Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and Carcinoma. Dig. Dis. Sci 54, 2109–2117 (2009).
    1. Nakazawa T et al. Global histone modification of histone H3 in colorectal cancer and its precursor lesions. Hum. Pathol 43, 834–842 (2012).
    1. Karczmarski J et al. Histone H3 lysine 27 acetylation is altered in colon cancer. Clin. Proteomics 11, 24 (2014).
    1. Gezer U et al. Characterization of H3K9me3- and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer. Tumor Biol. 34, 329–336 (2013).
    1. Gezer U et al. Histone Methylation Marks on Circulating Nucleosomes as Novel Blood-Based Biomarker in Colorectal Cancer. Int. J. Mol. Sci 16, 29654–29662 (2015).
    1. Tamagawa H et al. The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer. Oncol. Rep 27, 637–42 (2012).
    1. Yokoyama Y et al. Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo. Cancer Sci. 104, 889–895 (2013).
    1. Benard A et al. Histone trimethylation at H3K4, H3K9 and H4K20 correlates with patient survival and tumor recurrence in early-stage colon cancer. BMC Cancer 14, 531 (2014).
    1. Benard A et al. Nuclear expression of histone deacetylases and their histone modifications predicts clinical outcome in colorectal cancer. Histopathology 66, 270–82 (2015).
    1. Benard A et al. Prognostic Value of Polycomb Proteins EZH2, BMI1 and SUZ12 and Histone Modification H3K27me3 in Colorectal Cancer. PLoS One 9, e108265 (2014).
    1. Bovell L et al. miRNAs are stable in colorectal cancer archival tissue blocks. Front. Biosci. (Elite Ed) 4, 1937–40 (2012).
    1. Peng Q et al. The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. Oncotarget 8, 44893–44909 (2017).
    1. Zhang Y, Guo C-C, Guan D-H, Yang C-H & Jiang Y-H Prognostic Value of microRNA-224 in Various Cancers: A Meta-analysis. Arch. Med. Res 48, 472–482 (2017).
    1. Hao H et al. Diagnostic and prognostic value of miR-106a in colorectal cancer. Oncotarget 8, 5038–5047 (2017).
    1. Zhi ML, Liu ZJ, Yi XY, Zhang LJ & Bao YX Diagnostic performance of microRNA-29a for colorectal cancer: a meta-analysis. Genet. Mol. Res 14, 18018–25 (2015).
    1. Yang X et al. MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: a systematic review and meta-analysis. PLoS One 9, e88745 (2014).
    1. Sun G et al. Signature miRNAs in colorectal cancers were revealed using a bias reduction small RNA deep sequencing protocol. Oncotarget 7, 3857–72 (2016).
    1. Bastaminejad S et al. Investigation of MicroRNA-21 Expression Levels in Serum and Stool as a Potential Non-Invasive Biomarker for Diagnosis of Colorectal Cancer. Iran. Biomed. J 21, 106–13 (2017).
    1. Toiyama Y et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 105, 849–859 (2013).
    1. Mima K et al. MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival. Clin. Cancer Res 22, 3841–8 (2016).
    1. Caramés C et al. MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int. J. Colorectal Dis 30, 899–906 (2015).
    1. Schetter AJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299, 425–36 (2008).
    1. Liu K et al. Increased expression of microRNA-21and its association with chemotherapeutic response in human colorectal cancer. J. Int. Med. Res 39, 2288–95 (2011).
    1. Ng EKO et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58, 1375–81 (2009).
    1. Wu CW et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 61, 739–45 (2012).
    1. Uratani R et al. Diagnostic Potential of Cell-Free and Exosomal MicroRNAs in the Identification of Patients with High-Risk Colorectal Adenomas. PLoS One 11, e0160722 (2016).
    1. Ke T-W, Wei P-L, Yeh K-T, Chen WT-L & Cheng Y-W MiR-92a Promotes Cell Metastasis of Colorectal Cancer Through PTEN-Mediated PI3K/AKT Pathway. Ann. Surg. Oncol 22, 2649–55 (2015).
    1. Elshafei A, Shaker O, Abd El-Motaal O & Salman T The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study. Tumour Biol. 39, 1010428317705765 (2017).
    1. Zhou J et al. 5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro. Oncol. Rep 23, 121–8 (2010).
    1. Du M et al. Clinical potential role of circulating microRNAs in early diagnosis of colorectal cancer patients. Carcinogenesis 35, 2723–30 (2014).
    1. Kanaan Z et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg 256, 544–551 (2012).
    1. Ogata-Kawata H et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One 9, e92921 (2014).
    1. Liu G-HH et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol 34, 2175–2181 (2013).
    1. Liu H-N et al. Serum microRNA signatures and metabolomics have high diagnostic value in colorectal cancer using two novel methods. Cancer Sci. 109, 1185–1194 (2018).
    1. Chang P-Y et al. MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection. Oncotarget 7, 10663–75 (2016).
    1. Herreros-Villanueva M et al. Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer. Clin. Transl. Gastroenterol 10, e00003 (2019).
    1. Zheng G et al. Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma. Br. J. Cancer 111, 1985–92 (2014).
    1. Huang Z et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. cancer 127, 118–26 (2010).
    1. Kjersem JB et al. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol 8, 59–67 (2014).
    1. Zhao W, Song M, Zhang J, Kuerban M & Wang H Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma. Int. J. Clin. Exp. Pathol 8, 14131–40 (2015).
    1. Svoboda M et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis 35, 1510–5 (2014).
    1. Alaiyan B et al. Differential expression of colon cancer associated transcript1 (CCAT1) along the colonic adenoma-carcinoma sequence. BMC Cancer 13, 196 (2013).
    1. Nissan A et al. Colon cancer associated transcript-1: A novel RNA expressed in malignant and pre-malignant human tissues. Int. J. Cancer 130, 1598–1606 (2012).
    1. He X et al. C-Myc-activated long noncoding RNA CCAT1 promotes colon cancer cell proliferation and invasion. Tumour Biol. 35, 12181–8 (2014).
    1. Ozawa T et al. CCAT1 and CCAT2 long noncoding RNAs, located within the 8q.24.21 ‘gene desert’, serve as important prognostic biomarkers in colorectal cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol 28, 1882–1888 (2017).
    1. Yin D et al. Long noncoding RNA GAS5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Med. Oncol 31, 253 (2014).
    1. Li Y et al. Long non-coding RNA growth arrest specific transcript 5 acts as a tumour suppressor in colorectal cancer by inhibiting interleukin-10 and vascular endothelial growth factor expression. Oncotarget 8, 13690–13702 (2017).
    1. Baretti M & Azad NS The role of epigenetic therapies in colorectal cancer. Curr. Probl. Cancer (2018). doi:10.1016/j.currproblcancer.2018.03.001
    1. Verheul HMW, Qian DZ, Carducci MA & Pili R Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemother. Pharmacol 60, 329–339 (2007).
    1. Abdelfatah E, Kerner Z, Nanda N & Ahuja N Epigenetic therapy in gastrointestinal cancer: the right combination. Therap. Adv. Gastroenterol 9, 560–579 (2016).
    1. Ikehata M et al. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells. Biol. Pharm. Bull 37, 67–73 (2014).
    1. Flis S, Gnyszka A & Flis K DNA Methyltransferase Inhibitors Improve the Effect of Chemotherapeutic Agents in SW48 and HT-29 Colorectal Cancer Cells. PLoS One 9, e92305 (2014).
    1. Overman MJ et al. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget 7, 67495–67506 (2016).
    1. Kim JC et al. In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer. Anticancer Res. 29, 3027–34 (2009).
    1. Fakih MG, Groman A, McMahon J, Wilding G & Muindi JR A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. Cancer Chemother. Pharmacol 69, 743–751 (2012).
    1. Humeniuk R, Mishra PJ, Bertino JR & Banerjee D Epigenetic reversal of acquired resistance to 5-fluorouracil treatment. Mol. Cancer Ther 8, 1045–1054 (2009).
    1. Fazzone W, Wilson PM, Labonte MJ, Lenz H-J & Ladner RD Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int. J. cancer 125, 463–73 (2009).
    1. Lou Y et al. Combination of Gefitinib and DNA Methylation Inhibitor Decitabine Exerts Synergistic Anti-Cancer Activity in Colon Cancer Cells. PLoS One 9, e97719 (2014).
    1. Mao M et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin. Cancer Res 19, 657–67 (2013).
    1. Abaza M-SI, Bahman A-M & Al-Attiyah R Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells. Int. J. Oncol 44, 105–28 (2014).
    1. Garrido-Laguna I et al. A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest. New Drugs 31, 1257–64 (2013).
    1. He G, Wang Y, Pang X & Zhang B Inhibition of autophagy induced by TSA sensitizes colon cancer cell to radiation. Tumour Biol. 35, 1003–11 (2014).
    1. Kim K et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. U. S. A 111, 11774–9 (2014).
    1. Yu G et al. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment. Cellular and Molecular Immunology 16, 1–9 (2018).
    1. US National Library of Medicine. (2019).
    1. Lee JJ et al. Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer. J. Clin. Oncol 35, 3054–3054 (2017).
    1. US National Library of Medicine. (2019).
    1. US National Library of Medicine. (2019).
    1. Romain B et al. Histone hypoacetylation contributes to CXCL12 downregulation in colon cancer: impact on tumor growth and cell migration. Oncotarget 8, 38351–38366 (2017).
    1. Huang Z et al. Lysine-specific demethylase 1 (LSD1/KDM1A) contributes to colorectal tumorigenesis via activation of the Wnt/β-catenin pathway by down-regulating Dickkopf-1 (DKK1) [corrected]. PLoS One 8, e70077 (2013).
    1. Hsu H-C et al. CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression. J. Cancer Res. Clin. Oncol 141, 11–21 (2015).
    1. Rotili D et al. Pan-Histone Demethylase Inhibitors Simultaneously Targeting Jumonji C and Lysine-Specific Demethylases Display High Anticancer Activities. J. Med. Chem 57, 42–55 (2014).
    1. Beg MS et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest. New Drugs 35, 180–188 (2017).
    1. Titze-de-Almeida R, David C & Titze-de-Almeida SS The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market. Pharm. Res 34, 1339–1363 (2017).
    1. Watts JK & Corey DR Silencing disease genes in the laboratory and the clinic. J. Pathol 226, 365–379 (2012).
    1. Singh A, Trivedi P & Jain NK Advances in siRNA delivery in cancer therapy. Artif. Cells, Nanomedicine, Biotechnol 46, 274–283 (2018).
    1. Nedaeinia R et al. Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer. J Cell Biochem 118, 4129–4140 (2017).
    1. Turajlic S, Sottoriva A, Graham T & Swanton C Resolving genetic heterogeneity in cancer. Nat. Rev. Genet (2019). doi:10.1038/s41576-019-0114-6
    1. Martínez-Cardús A et al. Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. Gastroenterology 151, 961–972 (2016).
    1. Davalos V et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 31, 2062–2074 (2012).
    1. Chen T et al. MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1alpha (FIH-1). Cancer Biol Ther 15, 516–523 (2014).
    1. Tang W et al. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. Br. J. Cancer 110, 450–458 (2014).
    1. Nagel R et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 68, 5795–5802 (2008).
    1. Toiyama Y et al. A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated Colorectal Cancer. Gastroenterology 153, 1634–1646.e8 (2017).

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する